Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07551778Phase 1Not Yet Recruiting

Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors

Role: lead

NCT06783049Not ApplicableRecruiting

Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System

Role: collaborator

NCT04833725Unknown

Screening and Early Warning of Chronic Obstructive Pulmonary Disease Combined With Sleep Respiratory Disease Based on Medical Internet of Things

Role: collaborator

All 3 trials loaded